Nasopharyngeal cancer response to induction chemotherapy
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This study looks at how well nasopharyngeal cancer (NPC) responds to the first round of chemotherapy before other treatments. It aims to see if the amount of tumor shrinkage can help predict outcomes and guide future care for people with advanced NPC.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a diagnosis of nasopharyngeal cancer that is stage III or IVa (locally advanced but not spread to other parts of the body).
- You must be in generally good health, able to carry out daily activities without significant help (ECOG score 0 or 1).
- You must not have had any previous cancer treatments like chemotherapy, radiation, or immunotherapy for this cancer.
- You cannot be pregnant or have another type of cancer.
- You are willing to follow the study schedule and procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to give radiation therapy after immunotherapy and chemotherapy for people with advanced nasopharyngeal cancer (NPC) that has partially shrunk. It aims to see if a different radiation schedule works better and has fewer side effects.
This trial tests whether switching to a different chemotherapy or going straight to radiation helps patients whose nasopharyngeal cancer did not shrink after two rounds of initial chemotherapy. It compares two approaches to see which is more effective for people whose cancer is stable or growing after induction chemotherapy.
This trial is for people with high-risk, newly diagnosed stage T3N1M0 nasopharyngeal cancer. It compares whether you need chemotherapy first (before radiation and chemotherapy together) to improve outcomes.
This trial compares two different chemotherapy combinations given before radiation for nasopharyngeal cancer. It is for patients with advanced but not metastatic disease who are in good overall health.
This trial tests a combination of two types of radiation therapy (standard SBRT and low-dose radiation) along with chemotherapy and an immunotherapy drug (PD-1 antibody) for people whose nasopharyngeal cancer has come back or spread. The goal is to see if this combination can better control the cancer.
This study looks at how the immune system responds to radiation therapy for nasopharyngeal cancer. It will use scans and blood tests to find markers that might predict how well treatment works.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.